Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom: Ergebnisse der ProComD-Studie

BACKGROUND: Androgen deprivation therapy (ADT) with a GnRH agonist or the GnRH antagonist degarelix is a central component in the treatment of prostate cancer (PCa). Little is currently known regarding the decision criteria. Knowledge of these could improve the success of treatment in the future. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehmann, J., Kluike, C. W., Haider, A., Haider, K. S, Baumann, S., Flesch, M., Gedamke, M., Kägebein, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Originalien
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831365/
https://www.ncbi.nlm.nih.gov/pubmed/34402941
http://dx.doi.org/10.1007/s00120-021-01620-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831365/
https://www.ncbi.nlm.nih.gov/pubmed/34402941
http://dx.doi.org/10.1007/s00120-021-01620-7

Ejemplares similares